Suven Life Sciences Ltd. - Quarterly/Annual Result Disclosures and Notes dated 31 Dec 2018

1). The above financial results were reveiwed by Audit Committee of the Board and approved by the Board of Directors' at their Meeting held on 05th February, 2019 and the same reviewed by the Statutory Auditors.

2). Effective from 1st April 2018, the company has adopted Ind AS-115, "Revenue from contract with customers". The application of Ind AS-115 does not have any significant impact on recognition and measurement of revenue from operations and other related items in the financial results of the company.

3). The Board has declared an Interim Dividend of Rs. 1.50 per equity share (150% of face value of Rs. 1.00/- each) for the financial year 2018-19, The outflow on account of Interim dividend including dividend distribution tax is Rs. 2301.69 lakhs.

4). The corresponding previous period figures have been regrouped / reclassified where ever necessary.